News

Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital

Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further develop Enlaza’s proprietary covalent protein technologies and to support advancement of wholly owned pipeline programs to the clinic. Lei...

Arsenal Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of AB-2100 in Development as a Treatment for Clear-cell Renal Cell Carcinoma

Arsenal Biosciences, a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that the first patient had been dosed with AB-2100 in a multi-center, open-label Phase 1/2 clinical trial for patients with clear-cell renal...

Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology

Shinobi Therapeutics, a biotechnology company developing a new class of immune evasive iPS cell therapies, today announced a partnership with Panasonic Holdings Corp and Kyoto University's Center for iPS Cell Research and Application (CiRA). Through this strategic collaboration, the organizations...

Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting

Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for the potential treatment of neurological disorders, today will present updated preliminary data from its ongoing open-label Phase 1/2 clinical trial of NRTX-1001 in adults with drug-...

Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting. In a new study, Exai’s novel RNA- and AI-based liquid biopsy platform demonstrated stage I breast cancer detection sensitivity of 90% and ductal carcinoma in situ (DCIS)...

EpiBiologics Advances Degraders of Membrane-Bound Proteins

EpiBiologics, a preclinical stage company advancing new bispecific antibody therapeutics for extracellular protein degradation, is presenting data today on its EpiTAC protein degraders in oncology demonstrating robust in vivo anti-tumor activity and survival benefit. EpiTAC bispecific antibodies...

Hydronovo ITP receives $2.3 million CIRM Translational Research Grant

C-DOCTOR Interdisciplinary Translational Project Team, Hydronovo, received a $2.3 million California Institute for Regenerative Medicine (CIRM) Translational Stage research grant to fund the development of their small molecule therapy and related translational activities.

Sira Medical Wins FDA Clearance for Augmented Reality Preoperative Surgical Planning Software

The U.S. Food and Drug Administration granted Sira Medical clearance for its augmented reality preoperative surgical planning application, which provides clinicians with advanced imaging to assist in making key patient management decisions.

Nested Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NST-628, a Novel Pan-RAF/MEK Molecular Glue

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for NST-628 for the treatment of patients...

J&J and Trial Library expand partnership on recruitment tools aimed at diversity

Johnson & Johnson Innovative Medicine and Trial Library have expanded a partnership to integrate the latter's clinical trial discovery platform into the pharma’s oncology clinical development and medical affairs programs. In a March 21 press release about the development, Trial Library CEO and...